Analyst consensus rating
MBX Biosciences Analyst Rating: Strong Buy
MBX is rated Strong Buy by 10 analysts with a $88.40 target. As of 2026-08-19.
Direct answer
MBX Biosciences's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $88.40.
Forecast evidence checked August 19, 2026.
Get free MBX Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $66.91
- Average price target
- $88.40
- High price target
- $121.00
- Low price target
- $70.00
- Low target gap
- +4.6%
- Target upside
- +32.1%
- High target gap
- +80.8%
- Target range width
- 76.2%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for MBX Biosciences?
MBX Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $88.40.
How far are MBX Biosciences's low and high targets from the recorded price?
The low target implies +4.6%, while the high target implies +80.8%.
How many analysts are included in MBX Biosciences's consensus?
The verified consensus includes 10 analysts.
How is MBX Biosciences's target upside or downside calculated?
The average target of $88.40 is divided by the recorded price of $66.91, then one is subtracted to produce +32.1%. This does not guarantee a future return.
When was MBX Biosciences's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.